Skip to main content
SpringerLink
Log in
SpringerLink
Log in

Da Qing, Finnish DPP, Tripod, and Dream: Lifestyle and Thiazolidinediones in the Prevention of Diabetes

  • Chapter
  • First Online:
Prevention of Type 2 Diabetes

  • 2096 Accesses

Abstract

Nearly one in seven adults in the United States has diabetes—but more than twice that number are at risk of diabetes, based on impaired glucose tolerance (IGT, 2-h glucose >140 and <200 mg/dL) or impaired fasting glucose (IFG, fasting glucose ≥100 and ≤126 mg/dL) based on an oral glucose tolerance test (OGTT) [1]. In the world, the prevalence of these diabetes risk states exceeds 8% of the adult population [2]. Given the high complication rates of diabetes, a great deal of interest has focused on measures to reduce the progression of this risk state. We review the results of two studies of lifestyle modification and two studies of thiazolidinedione administration in the prevention of diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care. 2009;32:287–94.

    Article  PubMed  Google Scholar 

  2. International Diabetes Federation. Fact sheet: impaired glucose tolerance (IGT); 2011. http://www.idf.org/fact-sheets/impaired-glucose-tolerance. Accessed 31 March 2011.

  3. Hu YH, Pan XR, Liu PA, Li GW, Howard BV, Bennett PH. Coronary heart disease and diabetic retinopathy in newly diagnosed diabetes in Da Qing, China: the Da Qing IGT and Diabetes Study. Acta Diabetol. 1991;28:169–73.

    Article  PubMed  CAS  Google Scholar 

  4. Pan XR, Hu YH, Li GW, Liu PA, Bennett PH, Howard BV. Impaired glucose tolerance and its relationship to ECG-indicated coronary heart disease and risk factors among Chinese. Da Qing IGT and diabetes study. Diabetes Care. 1993;16:150–6.

    Article  PubMed  CAS  Google Scholar 

  5. Li G, Chen X, Jang Y, Wang J, Xing X, Yang W, et al. Obesity, coronary heart diseaase risk ­factors and diabetes in Chinese: an approach to the criteria of obesity in the Chinese ­population. Obes Rev. 2002;3:167–72.

    Article  PubMed  CAS  Google Scholar 

  6. Pan XR, Li GW, Hu YH, Wang XJ, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care. 1997;20:537–44.

    Article  PubMed  CAS  Google Scholar 

  7. Li GW, Hu YH, Yang WY, Jiang YY, Wang JP, Xiao JZ, et al. Effects of insulin resistance and insulin secretion on the efficacy of interventions to retard development of type 2 diabetes ­mellitus: the DA Qing IGT and Diabetes Study. Diabetes Res Clin Pract. 2002;58:193–200.

    Article  PubMed  CAS  Google Scholar 

  8. Li GW, Zhang P, Wang JP, Gregg EW, Yang WY, Gong QH, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371:1783–9.

    Article  PubMed  Google Scholar 

  9. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.

    Article  Google Scholar 

  10. Gong Q, Gregg EW, Wang J, An Y, Zhang P, Yang W, et al. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study. Diabetologia. 2011;54:300–7.

    Article  PubMed  CAS  Google Scholar 

  11. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al.; Finnish Diabetes. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.

    Article  Google Scholar 

  12. Ilanne Parikka P, Eriksson JG, Lindstrom J, et al. Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study. Diabetes Care. 2008;31:805–7.

    Article  PubMed  Google Scholar 

  13. Uusitupa M, Lindi V, Louheranta A, Salopuro T, Lindstro J, Tuomilehto J; Finnish Diabetes Prevention Study Group. Changing lifestyles of people with impaired glucose tolerance 4-year results from the Finnish Diabetes Prevention Study. Diabetes. 2003;52:2532–8.

    Article  Google Scholar 

  14. Uusitupa M, Peltonen M, Lindström J, Aunola S, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, et al.; Finnish Diabetes Prevention Study Group. Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study—secondary analysis of the randomized trial. PLoS One. 2009;4:e5656.

    Article  Google Scholar 

  15. Lindström J, Ilanne Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemiö K, et al.; Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet. 2006;368:1673–9.

    Article  Google Scholar 

  16. Lindström J, Peltonen M, Eriksson JG, Louheranta A, Fogelholm M, Uusitupa M, et al. High-fibre, low-fat diet predicts long-term weight loss and decreased type 2 diabetes risk: the Finnish Diabetes Prevention Study. Diabetologia. 2006;49:912–20.

    Article  PubMed  Google Scholar 

  17. Ilanne-Parikka P, Laaksonen DE, Eriksson JG, Lakka TA, Lindstr J, Peltonen M, et al.; Finnish Diabetes Prevention Study Group. Leisure-time physical activity and the metabolic syndrome in the Finnish diabetes prevention study. Diabetes Care. 2010;33:1610–7.

    Article  Google Scholar 

  18. Tuomilehto H, Peltonen M, Partinen M, Lavigne G, Eriksson JG, Herder C, et al.; Finnish Diabetes Prevention Study Group. Sleep duration, lifestyle intervention, and incidence of type 2 diabetes in impaired glucose tolerance: the Finnish Diabetes Prevention Study. Diabetes Care. 2009;32:1965–71.

    Article  Google Scholar 

  19. Herder C, Peltonen M, Koenig W, Sütfels K, Lindström J, Martin S, et al.; Finnish Diabetes Prevention Study Group. Anti-inflammatory effect of lifestyle changes in the Finnish Diabetes Prevention Study. Diabetologia. 2009;52:433–42.

    Article  Google Scholar 

  20. Makrilakis K, Liatis S, Grammatikou S, Perrea D, Stathi C, Tsiligrosa P, Katsilambros N. Validation of the Finnish diabetes risk score (FINDRISC) questionnaire for screening for undiagnosed type 2 diabetes, dysglycaemia and the metabolic syndrome in Greece. Diabetes Metab. 2011;37:144–51.

    Google Scholar 

  21. Schulze MB. Determinants for the effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study: response to Lindstrom et al. Diabetes Care. 2008;31:857–62.

    Article  PubMed  Google Scholar 

  22. Uusitupa MI, Stančáková A, Peltonen M, Eriksson JG, Lindström J, Aunola S, et al. Impact of positive family history and genetic risk variants on the incidence of diabetes the Finnish Diabetes Prevention Study. Diabetes Care. 2011;34:418–23.

    Article  PubMed  Google Scholar 

  23. McCarthy MI, Zeggini E. Genome-wide association studies in type 2 diabetes. Curr Diab Rep. 2009;9:164–71.

    Article  PubMed  CAS  Google Scholar 

  24. Grant RW, Hivert M, Pandiscio JC, Florez JC, Nathan DM, Meigs JB. The clinical application of genetic testing in type 2 diabetes: a patient and physician survey. Diabetologia. 2009;52:2299–305.

    Article  PubMed  CAS  Google Scholar 

  25. Voight BF, Scott LJ, Steinthorsdottir V, et al.; MAGIC Investigators; GIANT Consortium. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42:579–89.

    Article  Google Scholar 

  26. Grant RW, Hivert M, Pandiscio JC, Florez JC, Nathan DM, Meigs JB. The clinical application of genetic testing in type 2 diabetes: a patient and physician survey. Diabetologia. 2009;52:2299–305.

    Article  PubMed  CAS  Google Scholar 

  27. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008;359:2220–32.

    Article  PubMed  CAS  Google Scholar 

  28. Cornelis MC, Qi L, Zhang C, et al. Joint effects of common genetic variants on the risk for type 2 diabetes in U.S. men and women of European ancestry. Ann Intern Med. 2009;150:541–50.

    PubMed  Google Scholar 

  29. Todorova B, Kubaszek A, Pihlajamäki J, Lindström J, Eriksson J, Valle TT, et al. The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study. J Clin Endocrinol Metab. 2004;89:2019–23.

    Article  PubMed  CAS  Google Scholar 

  30. Siitonen N, Pulkkinen L, Lindström J, Kolehmainen M, Eriksson JG, Venojärvi M, et al. Association of ADIPOQ gene variants with body weight, type 2 diabetes and serum adiponectin concentrations: the Finnish Diabetes Prevention Study. BMC Med Genet. 2011;12:5.

    Article  PubMed  CAS  Google Scholar 

  31. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. 2002;51:2796–803.

    Article  PubMed  CAS  Google Scholar 

  32. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Berkowitz K, Marroquin A, et al. Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes. 2000;49:782–8.

    Article  PubMed  CAS  Google Scholar 

  33. Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes. 2006;55:517–22.

    Article  PubMed  CAS  Google Scholar 

  34. Xiang AH, Hodis HN, Kawakubo M, Peters RK, Kjos SL, Marroquin A, et al. Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes. Atherosclerosis. 2008;199:207–14.

    Article  PubMed  CAS  Google Scholar 

  35. Gerstein HC, Yusuf S, Holman R, Bosch J, Pogue J; DREAM Trial Investigators. Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia. 2004;47:1519–27.

    Article  Google Scholar 

  36. McDonald SD, Yusuf S, Sheridan P, Anand SS, Gerstein HC; Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Trial Investigators. Dysglycemia and a history of reproductive risk factors. Diabetes Care. 2008;31:1635–8.

    Article  Google Scholar 

  37. DREAM Trial Investigators, Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551–62.

    Article  PubMed  Google Scholar 

  38. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096–105.

    Article  PubMed  CAS  Google Scholar 

  39. Boyko EJ, Gerstein HC, Mohan V, Yusuf S, Sheridan P, Anand S, et al.; DREAM Trial Investigators. Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabet Med. 2010;27:1226–32.

    Google Scholar 

  40. DREAM Trial Investigators, Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. 2008;31:1007–14.

    Article  PubMed  CAS  Google Scholar 

  41. Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, et al.; DREAM Investigators. Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. Diabetes Care. 2010;33:2250–3.

    Article  Google Scholar 

  42. Lonn EM, Gerstein HC, Sheridan P, Smith S, Diaz R, Mohan V, et al.; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) and STARR Investigators. Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). J Am Coll Cardiol. 2009;53:2028–35.

    Article  Google Scholar 

  43. Hanley AJ, Zinman B, Sheridan P, Yusuf S, Gerstein HC; Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) Investigators. Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. Diabetes Care. 2010;33:608–13.

    Article  Google Scholar 

  44. DREAM On (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication Ongoing Follow-up) Investigators, Gerstein HC, Mohan V, Avezum A, Bergenstal RM, Chiasson JL, et al. Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia. 2011;54:487–95.

    Article  PubMed  CAS  Google Scholar 

  45. Tuomilehto J, Wareham N. Glucose lowering and diabetes prevention: are they the same? Lancet. 2006;368:1218–9.

    Article  PubMed  Google Scholar 

  46. Davidson MB. Clinical implications of the DREAM Study. Diabetes Care. 2007;30:418–20.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetes Medical Center, Boney ha Ir 9, Tel Aviv, 61480, Israel

    Mariela Glandt MD (Medical Director)

  2. Department of Medicine, Mount Sinai School of Medicine, 35 East 85th Street, New York, NY, 10028, USA

    Zachary Bloomgarden MD

Authors
  1. Mariela Glandt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zachary Bloomgarden MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zachary Bloomgarden MD .

Editor information

Editors and Affiliations

  1. , Department of Medicine, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, 10029, USA

    Derek LeRoith

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Glandt, M., Bloomgarden, Z. (2012). Da Qing, Finnish DPP, Tripod, and Dream: Lifestyle and Thiazolidinediones in the Prevention of Diabetes. In: LeRoith, D. (eds) Prevention of Type 2 Diabetes. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3314-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3314-9_11

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-3313-2

  • Online ISBN: 978-1-4614-3314-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation